FLSM
NUVB icon

Frazier Life Sciences Management’s Nuvation Bio NUVB Stock Holding History

Frazier Life Sciences Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,218,236
Closed -$2.79M – 52
2024
Q3 		$2.79M Buy
+1,218,236
New +$3.72M 0.11% 51

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Frazier Life Sciences Management's NUVB Position: Q4 2024 in Review

Frazier Life Sciences Management sold out of Nuvation Bio (NUVB) in Q4 2024, closing a stake of 1,218,236 shares — an estimated $2.79M sold.

Frazier Life Sciences Management first reported a position in NUVB in Q3 2024 and held it in 1 quarter. The position peaked at $2.79M in Q3 2024. 160 funds tracked by Wall St. Rank hold NUVB as of Q4 2024.

  • Frazier Life Sciences Management reported no remaining Nuvation Bio position as of Q4 2024 after selling out during the quarter.
  • Frazier Life Sciences Management sold 1,218,236 Nuvation Bio shares in Q4 2024, an estimated $2.79M.
  • Frazier Life Sciences Management first reported a position in Nuvation Bio in Q3 2024 and held it in 1 quarter.
  • Frazier Life Sciences Management's Nuvation Bio position peaked at $2.79M in Q3 2024.
  • 160 funds tracked by Wall St. Rank held Nuvation Bio as of Q4 2024.

Based on Frazier Life Sciences Management's 13F filing for Q4 2024, filed 18 Feb 2025.